EBIT (Annual)

EBIT: Income before interest and taxes.

Collegium Pharmaceutical, Inc. (COLL) had EBIT of $179.64M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$780.57M
Net Income	$62.87M
Cost of Goods Sold	$317.31M
Gross Profit	$463.26M
Operating Expenses	$600.93M
Operating Income	$179.64M
Non-Operating Income/Expense	$-87.02M
Pre-Tax Income	$92.62M
Normalized Pre-Tax Income	$92.62M
Income after Taxes	$62.87M
Income from Continuous Operations	$62.87M
Consolidated Net Income/Loss	$62.87M
Normalized Income after Taxes	$62.87M
EBIT	$179.64M
EBITDA	$404.64M
Weighted-Average Shares Outstanding (Basic)	31.71M
Weighted-Average Shares Outstanding (Diluted)	39.70M
Earnings per Share (EPS) (Basic)	$1.98
Earnings per Share (EPS) (Diluted)	$1.73
Balance Sheet Financials
Current Assets	$691.41M
Property, Plant, and Equipment	$12.01M
Long-Term Assets	$965.42M
Total Assets	$1.66B
Current Liabilities	$440.03M
Long-Term Debt	$780.33M
Long-Term Liabilities	$915.13M
Total Liabilities	$1.36B
Common Equity	$301.68M
Tangible Shareholders Equity	$-513.76M
Shareholders Equity	$301.68M
Common Shares Outstanding	31.71M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$329.32M
Cash Flow from Investing Activities	$-63.53M
Cash Flow from Financial Activities	$-110.25M
Beginning Cash	$96.61M
End Cash	$252.16M
Increase/Decrease in Cash	$155.55M
Stock-Based Compensation	$41.91M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.57
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.72
Debt to Equity Ratio	2.68
Gross Margin	59.35%
Operating Margin	23.01%
EBIT Margin	23.01%
EBITDA Margin	51.84%
Pre-Tax Profit Margin	11.87%
Profit Margin	8.05%
Free Cash Flow	$327.58M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.47
Inventory Turnover	7.76
Receiveable Turnover	3.69
Days Sales in Receivables	98.82
Return on Equity	20.84%
Return on Tangible Equity	-12.24%
Return on Assets	3.79%
Return on Investments	5.81%
Book Value Per Share	$9.51
Free Cash Flow per Share	$8.25
Operating Cash Flow per Share	$8.29

Data from Zacks Investment Research, Inc.